DeepMatter Group Plc (AIM: DMTR, “Deepmatter”, the “Group”), the digital chemistry data and software company, has signed a multiyear database license agreement with Merck, a leading science and technology company, operating across Healthcare, Life Science and Electronics.
Pursuant to the agreement, DeepMatter will licence to the Life Science business sector of Merck certain proprietary data for machine learning-based applications. The terms of the agreement were not disclosed.
“We are delighted to announce an important licensing agreement with Merck, one of the leading companies using digitalisation in healthcare and life sciences to deliver our vision to provide the data that enables all medicines to be made in the best possible way,” said Mark Warne, CEO of DeepMatter.
Merck and Deepmatter will also explore ways to identify, acquire, generate and structure sets of chemical reaction data that can be used to enable scientists to develop new molecules faster and more efficiently which could encompass use of DeepMatter’s SmartChemistry® capabilities.
For more information contact
DeepMatter Group Plc
Mark Warne, Chief Executive Officer 0141 548 8156
Fraser Benson, Chief Financial Officer
